Collection of our favorite papers

If you're anything like us, you have a stack of publications by fellow scientists that you are eager to read.

We thought this felt a little bit like wanting to read a new book, but walking into the bookstore and feeling overwhelmed by all the awesome potential! Like us, I am sure you’re drawn to the employee recommendations, because at least someone you “know” read it and can give it a little more color than the book jacket does. Because of that, we have collected some of our favorite papers, and our colleagues are here to tell you why!

Rebekah Sayers

EMEAI Applications Lead, Life Science Research/OMICS – SCIEX

Rebekah Sayers

EMEAI Applications Lead, Life Science Research/OMICS – SCIEX

 

"Recently, the use of biomaterials to deliver neural stem cells (NSCs) during stem cell therapy to treat brain and spinal cord injuries has shown real promise for helping to avoid cell death. But traditional techniques for assessing the safety of stem cell nanoengineering fall short when it comes to providing insights into the subtleties of cellular physiology or regenerative capabilities. This paper is interesting for 2 reasons. First, it describes a novel application of a data-independent MS approach that uses proteomics to confirm there are no undesirable proteome changes caused by the process. And second, it's exciting to see MS technology being used to accelerate the incredibly important area of stem cell research."

 

Rebekah’s favorite paper

Safe nanoengineering and incorporation of transplant populations in a neurosurgical grade biomaterial, DuraGen Plus, for protected cell therapy applications

 

Jérémy Potriquet

Field Application and Market Development Specialist – SCIEX

Jérémy Potriquet

Field Application and Market Development Specialist – SCIEX

 

"I particularly love how this paper provides further evidence of the incredible reproducibility that mass spectrometry proteomics is able to achieve, even over an extended period of time and with large sample cohorts. This study not only provides evidence that modern quantitative proteomics is very reproducible in concordance with previously attempted large-scale qualitative comparisons, but also demonstrates the importance of data normalization when dealing with large batches of samples. This is particularly relevant for the ever-growing demand in highthroughput proteomics that is paving the way for clinical applications."

 

Jérémy’s favorite paper

Strategies to enable large-scale proteomics for reproducible research

 

Mackenzie Pearson

Staff Application Scientist – SCIEX

Mackenzie Pearson

Staff Application Scientist – SCIEX

 

"Advanced age, diabetes, obesity and heart disease are comorbidities that put COVID-19 patients into a high-risk group for severe disease. Who doesn’t know someone that might fall into one of these groups? Research has shown that changes in the lipidome play a huge role in many of the high-risk and severe disease groups for COVID-19 patients, and nothing has been more in the limelight of scientific research than COVID-19 recently. This paper shines light on how global lipidomic profile changes partnered with lipid mediator pathway markers—and their role in the immune response in this severe disease state—will help guide current and future treatments."

 

Mackenzie’s favorite paper

Cutting edge: Severe SARS-CoV-2 infection in humans is defined by a shift in the serum lipidome, resulting in dysregulation of eicosanoid immune mediators

 

Mark Cafazzo

Senior Director of Innovation – SCIEX

Mark Cafazzo

Senior Director of Innovation – SCIEX

 

"Unfortunately, everyone knows someone touched by Alzheimer’s or rheumatoid arthritis. Listening to Justyna’s talk about this work at the SCIEX ASMS user meeting, I really appreciated the clever way they harnessed biology to solve the challenging analytical problems around studying citrullinated proteins, and hopefully address diseases such as rheumatoid arthritis and Alzheimer’s."

 

Mark's favorite paper

Mapping citrullinated sites in multiple organs of mice using hypercitrullinated library

 

Arianna Jones

Global Strategic Marketing Manager,
Life Science Research – SCIEX

Arianna Jones

Global Strategic Marketing Manager, Life Science Research – SCIEX

 

"Anyone who’s ever studied post-translational modifications knows just how tricky they are to analyze using LC-MS! They’re hugely important for biomedical research, and yet it’s so tough to get enough sample. To study these essential functional proteins, it is critical to develop more efficient and flexible ways to analyze single and multiple PTMs in one go. This paper describes a unique “one-pot” workflow that, when combined with SWATH acquisition, offers comprehensive and quantitative results, giving researchers the ability to delve into simultaneous acetyl- and succinyl-lysine enrichment (and could be extensible to others!), and cuts the time for sample prep and MS data acquisition in half."

Arianna's favorite paper

Simultaneous quantification of the acetylome and succinylome by 'one-pot' affinity enrichment

Tom Knapman

Sr Manager, Strategic Marketing,
Brand and Creative – SCIEX

Tom Knapman

Sr Manager, Strategic Marketing, Brand and Creative – SCIEX

 

“If, like me, you’re one of those people who can’t stand the thought of someone touching your eye, the implications in this paper will really resonate. nAMD is a condition where abnormal blood vessel growth causes sight degeneration and ultimately blindness in elderly people. Currently the standard treatment is administration of anti-VEGF via a direct injection into the white of the eye. Ugh! As if that wasn’t bad enough, treatment is effective in only around 50% of cases, so there is a real need for markers to determine who will actually respond to the treatment. This paper describes a precision medicine approach using untargeted metabolomics to quantify serum metabolic signatures and predict response to anti-VEGF therapy.”

Tom's favorite paper

A serum metabolomics study of patients with nAMD in response to anti-VEGF therapy

Melanie Juba

Senior Manager, Biopharma Accurate Mass – SCIEX

Melanie Juba

Senior Manager, Biopharma Accurate Mass – SCIEX

 

"Within the first paragraph of this paper I was drawn in! What initially grabbed my attention was the devastating facts about heart failure and the challenges of diagnosis. The findings presented in the paper are much needed as we think about the possibility of identifying better predictors and new biomarkers of heart failure moving forward."

Melanie's favorite paper

Metabolic modulation predicts heart failure tests performance